Abstract

One of the problems currently faced in the management of SARS-CoV2 infection is the absence of specific treatments that have proven their usefulness and their safety in studies with statistical validity, which allows to justify on reasoned evidence its use. In the case of paediatric patients although there are no serious cases in proportion to adults, there is the ethical limitation of not having reliable data to be able to justify therapeutic interventions on scientific evidence and to date there are few studies that analyze the safety of certain drugs and have not been included in paediatric groups in the evaluation of the use of COVID-19 vaccines.